Immatics N.v. · NASDAQ:IMTX
Immatics — Investor Presentation (January 2021)
35 slides from Immatics's investor presentation, Jan 6, 2021
Slide 1: Unlocking Immunotherapies for Solid Cancer Patients
Unlocking Immunotherapies for Solid Cancer Patients Immatics Corporate Presentation, January 2021 Exhibit 99.1
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation (“Presentation”) is provided by Immatics N.V. (“Immatics” or the “Company”) for informational purposes only. The information contained herein does not purport to be all-inclusive and Immatics nor any of its affiliates nor any of its or their control person
Slide 3: Two Transformative Treatment Modalities, Differentiated Technologies, Strategic Collaborations
Two Transformative Treatment Modalities: Adoptive Cell Therapies and TCR Bispecifics Highly Differentiated Technologies to Identify True Cancer Targets and the Right TCRs Unlocking Immunotherapies for Solid Cancer Patients Strategic Collaborations with World-leading Industry Players
Slide 4: Limitations of Current Immunotherapies in Solid Cancer Patients
Limitations of Current Immunotherapies in Solid Cancer Patients … Driven by a Lack of Known Cancer-specific Targets 1 Chalmers et al., 2017; 2SEER Cancer Statistics Review, 1975-2017, Estimated New Cancer Cases for 2020 Checkpoint inhibitors mainly effective in tumors with high mutational burden min
Slide 5: Unlocking Immunotherapies by Intracellular Cancer Targets and Matching Right TCRs
Unlocking Immunotherapies for Solid Cancer Patients … by Intracellular Cancer Targets and Matching Right T cell Receptors (TCRs) Modified from Chandran et al., 2019 Intro
Slide 6: The Immatics Approach Based on 5 Defined Principles
The Immatics Approach to Disrupt Current Tumor Treatment Paradigms Based on 5 Defined Principals True Cancer Targets & Matching Right TCRs Targeted Approach in Two Distinct Modalities: Adoptive Cell Therapy & TCR Bispecifics Optimized Cell Therapy Products to Enhance T cell Persistence & Efficacy Di
Slide 7: Targeted Approach in Two Distinct Modalities
Immatics’ Targeted Approach in Two Distinct Modalities High tumor burden Lower tumor burden1 1 Patients at earlier stage of disease, de-bulked tumors, or late-stage patients with reduced tumor burden Specialized Centers All Hospitals & Out-Patient Intro
Slide 8: Immatics' Pipeline
Immatics’ Pipeline Modality Product Candidate Status Preclinical Phase 1a1 Phase 1b1 Phase 2 Phase 3 Autologous ACT ACTengine® IMA201 (MAGEA4/8) Proprietary ACTengine® IMA202 (MAGEA1) Proprietary ACTengine® IMA203 (PRAME) Proprietary ACTengine® IMA204 (COL6A3) Proprietary Autologous TCR-T ACT progra
Slide 9: Strategic Collaborations with World-leading Industry Players
Strategic Collaborations with World-leading Industry Players Validating Immatics’ Differentiated Technologies and Expertise 2017 Bispecific Cancer Immunotherapies $30m upfront 2 Immatics targets 2018 Bispecific Cancer Immunotherapies $54m upfront 3 Immatics targets 2019 Adoptive Cell Therapies $75m
Slide 10: Upcoming R&D Milestones in 2021
Upcoming R&D Milestones in 2021 1H 2021 2H 2021 ACTengine® IMA201, 202, 203: Initial Ph1a dose escalation read-out IMA201, 203: Additional Ph1a read-out IMA204 IND submission TCER® IMA401 IND submission Intro IMA202: Initial Ph1b dose expansion read-out IMA402 Start GMP manufacturing activities
Slide 11: Adoptive Cell Therapy
Adoptive Cell Therapy
Slide 12: ACTengine – Immatics' TCR-T Approach
ACTengine® – Immatics’ TCR-T Approach 1 IMA201, IMA202 and IMA203 in Ph1 clinical trials, IMA204 IND expected in 2H 2021 ACTengine® Key Differentiation Points High-density peptide targets designed for enhanced efficacy and matching highly specific TCRs with reduced risk for off-target toxicity Optim
Slide 13: ACTengine IMA201, IMA202 & IMA203 – Ongoing Clinical Trials
ACTengine® IMA201, IMA202 & IMA203 – Ongoing Clinical Trials ACT 1 Defined as copy number per cell determined by mass spectrometry-based AbsQuant® technology; 2 Applying XPRESIDENT®-guided off-target toxicity and similar peptide screening designed for reduced cross-reactivity; 3 Lymphodepletion 40 m
Slide 14: Optimized Cell Therapy Products to Enhance T cell Persistence & Efficacy
Optimized Cell Therapy Products to Enhance T cell Persistence & Efficacy Proprietary Manufacturing Process, designed to reduce manufacturing process to approx. 1 week shorten vein-to-vein time generate younger T cells with increased proliferative capacity improve engraftment and persistence in patie
Slide 15: Early Data in ACTengine Trials Pointing Towards Favorable Engraftment
Early Data in ACTengine® Trials Pointing Towards Favorable Engraftment Next Update: Combined initial data read-out expected in 1Q 20212 Molecular Immunomonitoring in Blood 201 Pt #1 202 Pt #1 203 Pt #1 202 Pt #2 IMA202 Pt#2 IMA203 Pt#1 Persistence of target-specific T cells over 4+ week observation
Slide 16: IMA204 – Disrupting the Tumor Microenvironment by Targeting Stroma
IMA204 – Disrupting the Tumor Microenvironment by Targeting Stroma Complete Tumor Eradication in vitro & in vivo1 by Affinity-enhanced IMA204 TCR Candidates One IMA204 TCR candidate leads to full functionality of both CD8 and CD4 T cells Control TCR2 Double mut. TCR1 Single mut. D7 D16 D22 D29 1 In
Slide 17: ACTallo IMA301 – Towards Off-the-shelf ACT
ACTallo® IMA301 – Towards Off-the-shelf ACT Effective Redirection of γδ T cells Using αβ TCR γδ T cell collection from healthy donor Off-the-shelf product Transduction Expansion Proprietary manufacturing protocol delivering robust expansion of γδ T cells with the potential for hundreds of doses from
Slide 18: Combating Tumor Heterogeneity & Escape through Multi-Target Approach
Combating Tumor Heterogeneity & Escape through Multi-Target Approach A Multi-Step Approach towards Highly Personalized Multi-TCR-T Therapy ACTolog® ACTengine® TCR-T Personalized Multi-TCR-T 1 2 3 Combination Trial ACTengine® Multi-TCR-T 4 >200 prioritized XPRESIDENT® targets Immatics TCR Warehouse M
Slide 19: TCR Bispecifics
oe Immiatics TCR Bispecifics
Slide 20: TCER – Immatics' TCR Bispecifics
TCER® – Immatics’ TCR Bispecifics Off-the-shelf Biologics Linking Immune Cells to Tumor Cells TCER®
Slide 21: TCER – Superior Proprietary TCR Bispecific Format
TCER® – Superior Proprietary TCR Bispecific Format TCER® T cell recruiting antibody pHLA targeting TCR Fc domain (silenced) with KiH technology TCER® Potency and stability of proprietary TCER® format is superior to six alternative TCR Bispecific formats1 1 Based on comparative preclinical testing
Slide 22: Preclinical POC for First TCER Program IMA401
Preclinical POC for First TCER® Program IMA401 TCER® IMA401 Targeting MAGEA4/8 Results in Tumor Eradication of Established Tumors * TCER® Study day -14: transplantation of tumor cells Study day 0: human PBMC transplantation & start of IMA401 weekly treatment Patient-Derived Tumor Model2 Preclinical
Slide 23: Discovery Platforms
oe Immiatics Discovery Platforms
Slide 24: True Cancer Targets & Matching Right TCRs
True Cancer Targets & Matching Right TCRs True Targets - expressed on cancer but not or to far lower extent on normal tissue Minimizing risk for on-target toxicity Right TCRs - highly specific and high affinity as outcome of stringent development process Minimizing risk for off-target toxicity (TCR
Slide 25: XPRESIDENT – Discovery of True Cancer Targets
XPRESIDENT® – Discovery of True Cancer Targets Quantitative, Ultra-Sensitive Mass Spectrometry Expertise Developed over Two Decades >400 million MS/MS spectra >20,000 experiments >8,000 peptides filed for patent >2,000 cancer & normal tissues analyzed by Quantitative, Ultra-Sensitive Mass Spectromet
Slide 26: MAGEA4/8 Target in IMA201 and IMA401 Programs
MAGEA4/8 Target in IMA201 and IMA401 Programs Unique Target Discovery and Characterization Capabilities >5-fold higher target density1 than a commonly used MAGEA4 target peptide MAGEA4/8 Peptide (quantitative mass spectrometry detection) Normal tissue Cancer tissue Status as of Oct 2020 Technology M
Slide 27: Development of the Right TCR – XCEPTOR
Development of the Right TCR – XCEPTOR® Unique Cross-Talk between Target and TCR Discovery TCR Bispecifics T cell engaging receptor (TCER®) Affinity-maturated natural TCR variable domains with nanomolar affinity and favorable specificity profile XPRESIDENT®-guided similar peptide counterselection du
Slide 28: XCEPTOR TCR Validation – Early De-selection of Cross-Reactive TCRs
XCEPTOR® TCR Validation – Early De-selection of Cross-Reactive TCRs ExDPIxxxY ESDPIVAQY Titin EPDPILDNY C19orf26 EVDPIRHYY MAGE B18 MAGE A3 EVDPIGHLY (target) Clinical fatalities have occurred in TCR-T trials using a titin cross-reactive TCR (published 2013) XPRESIDENT®-guided toxicity screening Dir
Slide 29: Corporate Information & Milestones
Corporate Information & Milestones
Slide 30: Continuously Growing IP Portfolio
Continuously Growing IP Portfolio Immatics’ Patent Estate – Territorial Coverage IP protection on >8000 cancer targets, TCRs and technology Immatics files patent applications in all major countries and regions >320 granted patents in the US >15 granted patents in Europe >1550 granted patents overall
Slide 31: Strong, Focused and Highly Integrated Trans-Atlantic Organization
Strong, Focused and Highly Integrated Trans-Atlantic Organization Senior Leadership, Business Development, Intellectual Property, Regulatory Affairs, Communications Senior Leadership, Research and Development (Adoptive Cell Therapy), CMC, Clinical Operations, Regulatory Affairs, QA/QC, HR, Investor
Slide 32: Experienced Global Leadership Team Across Europe and the US
Experienced Global Leadership Team Across Europe and the US Harpreet Singh Chief Executive Officer Co-Founder 20 yrs biotech experience Carsten Reinhardt Chief Development Officer >20 yrs pharma & biotech experience (Micromet, Roche, Fresenius) Rainer Kramer Chief Business Officer 25 yrs pharma & bi
Slide 33: Upcoming R&D Milestones in 2021
Upcoming R&D Milestones in 2021 1H 2021 2H 2021 ACTengine® IMA201, 202, 203: Initial Ph1a dose escalation read-out IMA201, 203: Additional Ph1a read-out IMA204 IND submission TCER® IMA401 IND submission Corporate IMA202: Initial Ph1b dose expansion read-out IMA402 Start GMP manufacturing activities
Slide 34: Immatics Key Take-Aways
Immatics Key Take-Aways Two Distinct Treatment Modalities: ACT & TCR Bispecifics Multiple ongoing Ph1a dose escalation clinical trials: Initial clinical data read out in Q1 2021 and additional clinical data in H2 2021 Proprietary cell manufacturing resulting in younger T cells for better engraftment
Slide 35: Thank you
DELIVERING THE POWER OF T CELLS TO CANCER PATIENTS Thank you www.immatics.com >< Jin] ¥ oe Immiatics